// App-Quantinova.ai

BSH19‐PO‐140 : Prognostic value of clone size in paroxysmal nocturnal hemoglobinuria (PNH) for thrombotic events in untreated patients in the International PNH Registry

Researchers

Presenter

  • R. Peffault De Latour

Principal Investigators

  • S. Gandhi

  • J.P. Maciejewski

  • A.G. Kulasekararaj

  • L. Larratt

  • R.S. Go

  • D. Dingli

  • A. Wilson

  • P. Gustovic

  • A.D. Kulagin

Medical Centers

  • Universite Paris-Diderot,

  • French Reference Center for Aplastic Anemia and PNH Hematology-Bone Marrow Transplantation, Research Institute for Microbial Diseases, Hôpital Saint-Louis AP-HP, Paris, France

  • Department of Haematological Medicine,King’s College Hospital, NIHR/Wellcome King’s Clinical Research Facility,London,United Kingdom

  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

  • Department of Surgery, University of Alberta, Edmonton, AB, Canada

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN

  • Alexion Pharmaceuticals, Inc., Boston, United States

  • Alexion Pharma GmbH, Zurich, Switzerland

  • Pavlov First Saint Petersburg State Medical University, Saint‐Petersburg, Russian Federation

Locations

  • France

  • United Kingdom

  • United States

  • Canada

  • Switzerland

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

  • Venous thrombosis

Biomarkers

  • Lactate dehydrogenase

  • Bone Mineral Density

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • NCT01374360

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved